Chinese chip stocks jump as Beijing reportedly warns against Nvidia’s H20
On Wednesday, Stifel analysts maintained a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a consistent price target of $345.00. The stock, which has delivered an impressive 80% return over the past year, currently trades near $267. According to InvestingPro data, analyst targets range from $212 to $500, reflecting diverse views on the company’s potential. The firm’s confidence is anchored in the potential success of Alnylam’s new drug, Amvuttra, particularly in treating cardiomyopathy (CM). According to Stifel, the company is making significant strides in ensuring that patients can readily access Amvuttra, leveraging the infrastructure and educational groundwork laid by the launch of their earlier drug for ATTR-PN. With revenue growing at 17.2% and a robust gross profit margin of 86%, Alnylam demonstrates strong commercial execution. InvestingPro subscribers can access 8 additional key insights about Alnylam’s financial health and growth prospects.
Stifel’s optimism also stems from the competitive positioning of Amvuttra, bolstered by the HELIOS-B study data, which suggests that the drug could become a first-line therapy for CM. The firm notes that patients currently on tafamidis who are progressing are likely to switch to Amvuttra as a second-line option due to its different mechanism of action.
Furthermore, Alnylam’s pipeline includes nucresiran, a next-generation silencer, which is expected to enter phase 3 trials for both CM and polyneuropathy (PN) later in the year. The management at Alnylam is hopeful that nucresiran’s deeper TTR knockdown and superior dosing schedule could offer further differentiation in the market.
While discussing the company’s multifactorial neuropathy (MFN) strategy, Stifel mentioned that Alnylam is currently adopting a wait-and-see approach due to limited details. Nonetheless, the discussions with Alnylam’s CFO Jeff Poulton and CMO Dr. Pushkal Garg during Stifel’s Boston Biotech Bus Tour have reinforced the analyst’s positive outlook on the company’s strategic moves and product launches. The company maintains a healthy financial position with a current ratio of 3.04 and operates with moderate debt levels. For a comprehensive analysis of Alnylam’s financial health and growth potential, investors can access the detailed Pro Research Report available on InvestingPro.
In other recent news, Alnylam Pharmaceuticals reported its first quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of -0.01 compared to the forecast of -0.93. The company’s revenue also exceeded projections, reaching $594.19 million against an anticipated $588.75 million. Despite these positive financial results, Alnylam’s stock experienced a decline in pre-market trading. Additionally, Alnylam reaffirmed its 2025 financial guidance, projecting product revenues between $2.05 billion and $2.25 billion, aligning closely with analysts’ estimates. H.C. Wainwright maintained a Buy rating on Alnylam with a price target of $500, citing the robust performance of AMVUTTRA (vutrisiran) as a key factor. Alnylam also announced plans to present key data on its amyloidosis treatments at an upcoming congress, highlighting the impact of vutrisiran on cardiovascular outcomes. Furthermore, the company recently held its Annual Meeting of Stockholders, where shareholders approved executive compensation plans and re-elected directors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.